Cargando…

Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study

OBJECTIVE: This study aimed to develop and externally validate a COVID-19 mortality risk prediction algorithm. DESIGN: Retrospective cohort study. SETTING: Five designated tertiary hospitals for COVID-19 in Hubei province, China. PARTICIPANTS: We routinely collected medical data of 1364 confirmed ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Jin, Hu, Weihua, Chen, Qijian, Li, Chang, Chen, Zaishu, Fan, Yanjie, Tian, Shuwei, Zhang, Zhuheng, Li, Bin, Ye, Qifa, Yue, Jiang, Wang, Qiao-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768618/
https://www.ncbi.nlm.nih.gov/pubmed/33361083
http://dx.doi.org/10.1136/bmjopen-2020-044028
_version_ 1783629196580356096
author Mei, Jin
Hu, Weihua
Chen, Qijian
Li, Chang
Chen, Zaishu
Fan, Yanjie
Tian, Shuwei
Zhang, Zhuheng
Li, Bin
Ye, Qifa
Yue, Jiang
Wang, Qiao-Li
author_facet Mei, Jin
Hu, Weihua
Chen, Qijian
Li, Chang
Chen, Zaishu
Fan, Yanjie
Tian, Shuwei
Zhang, Zhuheng
Li, Bin
Ye, Qifa
Yue, Jiang
Wang, Qiao-Li
author_sort Mei, Jin
collection PubMed
description OBJECTIVE: This study aimed to develop and externally validate a COVID-19 mortality risk prediction algorithm. DESIGN: Retrospective cohort study. SETTING: Five designated tertiary hospitals for COVID-19 in Hubei province, China. PARTICIPANTS: We routinely collected medical data of 1364 confirmed adult patients with COVID-19 between 8 January and 19 March 2020. Among them, 1088 patients from two designated hospitals in Wuhan were used to develop the prognostic model, and 276 patients from three hospitals outside Wuhan were used for external validation. All patients were followed up for a maximal of 60 days after the diagnosis of COVID-19. METHODS: The model discrimination was assessed by the area under the receiver operating characteristic curve (AUC) and Somers’ D test, and calibration was examined by the calibration plot. Decision curve analysis was conducted. MAIN OUTCOME MEASURES: The primary outcome was all-cause mortality within 60 days after the diagnosis of COVID-19. RESULTS: The full model included seven predictors of age, respiratory failure, white cell count, lymphocytes, platelets, D-dimer and lactate dehydrogenase. The simple model contained five indicators of age, respiratory failure, coronary heart disease, renal failure and heart failure. After cross-validation, the AUC statistics based on derivation cohort were 0.96 (95% CI, 0.96 to 0.97) for the full model and 0.92 (95% CI, 0.89 to 0.95) for the simple model. The AUC statistics based on the external validation cohort were 0.97 (95% CI, 0.96 to 0.98) for the full model and 0.88 (95% CI, 0.80 to 0.96) for the simple model. Good calibration accuracy of these two models was found in the derivation and validation cohort. CONCLUSION: The prediction models showed good model performance in identifying patients with COVID-19 with a high risk of death in 60 days. It may be useful for acute risk classification.
format Online
Article
Text
id pubmed-7768618
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77686182020-12-28 Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study Mei, Jin Hu, Weihua Chen, Qijian Li, Chang Chen, Zaishu Fan, Yanjie Tian, Shuwei Zhang, Zhuheng Li, Bin Ye, Qifa Yue, Jiang Wang, Qiao-Li BMJ Open Epidemiology OBJECTIVE: This study aimed to develop and externally validate a COVID-19 mortality risk prediction algorithm. DESIGN: Retrospective cohort study. SETTING: Five designated tertiary hospitals for COVID-19 in Hubei province, China. PARTICIPANTS: We routinely collected medical data of 1364 confirmed adult patients with COVID-19 between 8 January and 19 March 2020. Among them, 1088 patients from two designated hospitals in Wuhan were used to develop the prognostic model, and 276 patients from three hospitals outside Wuhan were used for external validation. All patients were followed up for a maximal of 60 days after the diagnosis of COVID-19. METHODS: The model discrimination was assessed by the area under the receiver operating characteristic curve (AUC) and Somers’ D test, and calibration was examined by the calibration plot. Decision curve analysis was conducted. MAIN OUTCOME MEASURES: The primary outcome was all-cause mortality within 60 days after the diagnosis of COVID-19. RESULTS: The full model included seven predictors of age, respiratory failure, white cell count, lymphocytes, platelets, D-dimer and lactate dehydrogenase. The simple model contained five indicators of age, respiratory failure, coronary heart disease, renal failure and heart failure. After cross-validation, the AUC statistics based on derivation cohort were 0.96 (95% CI, 0.96 to 0.97) for the full model and 0.92 (95% CI, 0.89 to 0.95) for the simple model. The AUC statistics based on the external validation cohort were 0.97 (95% CI, 0.96 to 0.98) for the full model and 0.88 (95% CI, 0.80 to 0.96) for the simple model. Good calibration accuracy of these two models was found in the derivation and validation cohort. CONCLUSION: The prediction models showed good model performance in identifying patients with COVID-19 with a high risk of death in 60 days. It may be useful for acute risk classification. BMJ Publishing Group 2020-12-23 /pmc/articles/PMC7768618/ /pubmed/33361083 http://dx.doi.org/10.1136/bmjopen-2020-044028 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Mei, Jin
Hu, Weihua
Chen, Qijian
Li, Chang
Chen, Zaishu
Fan, Yanjie
Tian, Shuwei
Zhang, Zhuheng
Li, Bin
Ye, Qifa
Yue, Jiang
Wang, Qiao-Li
Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
title Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
title_full Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
title_fullStr Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
title_full_unstemmed Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
title_short Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
title_sort development and external validation of a covid-19 mortality risk prediction algorithm: a multicentre retrospective cohort study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768618/
https://www.ncbi.nlm.nih.gov/pubmed/33361083
http://dx.doi.org/10.1136/bmjopen-2020-044028
work_keys_str_mv AT meijin developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT huweihua developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT chenqijian developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT lichang developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT chenzaishu developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT fanyanjie developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT tianshuwei developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT zhangzhuheng developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT libin developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT yeqifa developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT yuejiang developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy
AT wangqiaoli developmentandexternalvalidationofacovid19mortalityriskpredictionalgorithmamulticentreretrospectivecohortstudy